Epidemiology, pathogenesis, molecular characteristics, classification and prognosis of the diffuse large B-cell lymphoma
##plugins.themes.bootstrap3.article.sidebar##
##plugins.themes.bootstrap3.article.main##
Abstract
##plugins.themes.bootstrap3.article.details##
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright and grant the journal the first publication of original scientific articles under the Creative Commons Attribution 4.0 International License, which allows others to distribute work with acknowledgment of authorship and first publication in this journal.
References
Abu Shanab A.A. Salah. Modern advance for B-lymphopoiesis / Abushanab A.A. Salah // Сімейна медицина / Family medicine. – 2015. – no. 3(59). – P. 246–247.
Adams H. Diagnostic utility of the B-cell lineage markers CD20, CD79a, PAX5, and CD19 in paraffin-embedded tissues from lymphoid neoplasms / Adams H., Liebisch P., Schmid P. et al. // Appl. Immunohistochem. Mol. Morphol. – 2009. – Vol. 17. – P. 96–101. https://doi.org/10.1097/PAI.0b013e3181845ef4
Akyurek N. Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab / Akyurek N., Uner A., Benekli M. et al. // Cancer. – 2011. – Vol. 118. – P. 4173–4183. https://doi.org/10.1002/cncr.27396
A predictive model for aggressive non-Hodgkin’s lymphoma. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project // N Engl. J. Med. – 1993. – Vol. 329. – P. 987–994. https://doi.org/10.1056/NEJM199309303291402
Bakhshi A. Cloning the chromosomal breakpoint of t(14;18) human lymphomas: Clustering around JH on chromosome 14 and near a transcriptional unit on 18 / Bakhshi A. Jensen J.P., Goldman P. et al. // Cell. – 1985. – Vol. 41. – P. 899–906. https://doi.org/10.1016/S0092-8674(85)80070-2
Barrans S. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab / Barrans S. Crouch S., Smith A. et al. // J Clin. Oncol. – 2010. – Vol. 28. – P. 3360–3365. https://doi.org/10.1200/JCO.2009.26.3947
Bergsagel P.L. Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma / Bergsagel P.L. Chesi M., Nardini E. et al. // Proc Natl. Acad. Sci. U.S.A. – 1996. – Vol. 93. – P. 13931–13936. https://doi.org/10.1073/pnas.93.24.13931
Campo E. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications / Campo E., Swerdlow SH., Harris NL. et al. // Blood. – 2011. – Vol. 117. – P. 5019–5032. https://doi.org/10.1182/blood-2011-01-293050
Choi W.W. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy / Choi W.W., Weisenburger D.D., Greiner T.C. et al. // Clin. Cancer. Res. – 2009. – Vol. 15. – P. 5494–5502. https://doi.org/10.1158/1078-0432.CCR-09-0113
Colleoni G.W. Linfomas não-hodgkin: aspectos clínicos, prognósticos e terapêuticos na era do rituximabe / Colleoni G.W., Inaoka R.J. // Diálogo Científico. – 2007. – Vol. (Nov/Dec). – P. 19–22.
Compagno M. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma / Compagno M., Lim W.K., Grunn A. et al. // Nature. – 2009. – Vol. 459. – P. 717–721. https://doi.org/10.1038/nature07968
Davis R.E. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells / Davis RE., Brown KD., Siebenlist U. et al. // J Exp. Med. – 2001. – Vol. 194. – P. 1861–1874. https://doi.org/10.1084/jem.194.12.1861
Davis R.E. Chronic active B-cellreceptor signalling in diffuse large B-cell lymphoma / Davis R.E., Ngo VN., Lenz G. et al. // Nature. – 2010. – Vol. 463. – P. 88–92. https://doi.org/10.1038/nature08638
Friedberg J.W. Rituximab for early stage diffuse large B-cell lymphoma // Lancet Oncol. – 2006. – Vol. 7 (5). – P. 357–359. https://doi.org/10.1016/S1470-2045(06)70668-4
Fugmann S.D. The RAG proteins and V(D)J recombination: Complexes, ends, and transposition / Fugmann S.D., Lee A.I., Shockett P.E. et al. // Annu. Rev. Immunol. – 2000. – Vol. 18. – P. 495–527. https://doi.org/10.1146/annurev.immunol.18.1.495
Gomez-Abad C. PIM inhibition as a rational therapeutic approach in diffuse large B cell lymphoma / Gomez-Abad C., Pisonero H., Blanco-Aparicio C. // Ann. Oncol. – 2011. – Vol. 22. Abstract 154. https://doi.org/10.1093/annonc/mdr211
Gonçalves E.M. Linfomas difusos de grandes células B – factores de prognóstico clínicos [dissertation] // Porto: Universidade do Porto. – 1999. PDF
Goossens T. Frequent occurrence of deletions and duplications during somatic hypermutation: Implications for oncogene translocations and heavy chain disease / Goossens T., Klein U., Kuppers R. // Proc Natl Acad Sci USA. – 1998. – Vol. 95. – P. 2463–2468. https://doi.org/10.1073/pnas.95.5.2463
Hans C.P. Confirmation of the molecular classification of diffuse large Bcell lymphoma by immunohistochemistry using a tissue microarray / Hans C.P., Weisenburger D.D., Greiner T.C. et al. // Blood. – 2004. – Vol. 103. – P. 275–282. https://doi.org/10.1182/blood-2003-05-1545
Hill B.T. Cell of origin determination in diffuse large b-cell lymphoma: Performance of immunohistochemical (IHC) algorithms and ability to predict outcome / Hill B.T., Collie A.M.B., Radivoyevitch T. et al. // Blood. – 2011. – Vol. 118 (suppl 21):Abstract. 950. Full text
Iqbal J. BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab / Iqbal J., Meyer P.N., Smith L.M. et al. // Clin. Cancer Res. – 2011. – Vol. 17. – P. 7785–7795. https://doi.org/10.1158/1078-0432.CCR-11-0267
Joos S. Primary mediastinal (thymic) B-cell lymphoma is characterized by gains of chromosomal material including 9p and amplification of the REL gene / Joos S., Otano-Joos M.I., Ziegler S. et al. // Blood. – 1996. – Vol. 87. – P. 1571–1578. PDF
Kato M. Frequent inactivation of A20 in B-cell lymphomas / Kato M., Sanada M., Kato I. et al. // Nature. – 2009. – Vol. 459. – P. 712–716. https://doi.org/10.1038/nature07969
Klapper W. Structural aberrations affecting the MYC locus indicate a poor prognosis independent of clinical risk factors in diffuse large B-cell lymphomas treated within randomized trials of the German High-Grade Non-Hodgkin’s Lymphoma Study Group (DSHNHL) / Klapper W., Stoecklein H., Zeynalova S. et al. // Leukemia. – 2008. – Vol. 22. – P. 2226–2229. https://doi.org/10.1038/leu.2008.230
Kraus M. Survival of resting mature B lymphocytes depends on BCR signaling via the Igalpha/beta heterodimer / Kraus M., Alimzhanov M.B., Rajewsky N. et al. // Cell. – 2004. –Vol. 117. – P. 787–800. https://doi.org/10.1016/j.cell.2004.05.014
Lam L.T. Small molecule inhibitors of I kappa B kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling / Lam L.T., Davis R.E, Pierce J. et al. // Clin. Cancer Res. – 2005. – Vol. 11. – P. 28–40.
Lam L.T. Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma / Lam L.T., Wright G., Davis R.E. et al. // Blood. – 2008. – Vol. 111. – P. 3701–3713. https://doi.org/10.1182/blood-2007-09-111948
Lenz G. Aggressive lymphomas / Lenz G., Staudt L.M. // N. Engl. J. Med. – 2010. – Vol. 362. – P. 1417–1429. https://doi.org/10.1056/NEJMra0807082
Liu M. Two levels of protection for the B cell genome during somatic hypermutation / Liu M., Duke J.L., Richter D.J. et al. // Nature. – 2008. – Vol. 451. – P. 841–845. https://doi.org/10.1038/nature06547
Lohr J.G. Discovery and prioritization of somatic mutations in diffuse large Bcell lymphoma (DLBCL) by whole-exome sequencing / Lohr J.G., Stojanov P., Lawrence M.S. et al. // Proc. Natl. Acad. Sci. U.S.A. – 2012. – Vol. 109. – P. 3879–3884. https://doi.org/10.1073/pnas.1121343109
Lymphomas 2018. ESMO Pocket Guidelines. European Society by Medical Oncology, 191 p.
Manis J. P. Mechanism and control of class-switch recombination / Manis J.P., Tian M., Alt F.W. // Trends Immunol. – 2002. – Vol. 23. – P. 31–39. https://doi.org/10.1016/S1471-4906(01)02111-1
Meyer P.N. Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large Bcell lymphoma treated with rituximab. / Meyer P.N., Fu K., Greiner T.C. et al. // J. Clin. Oncol. – 2011. – Vol. 29. – P. 200–207. https://doi.org/10.1200/JCO.2010.30.0368
Migliazza A. Frequent somatic hypermutation of the 5-noncoding region of the BCL6 gene in B-cell lymphoma / Migliazza A., Martinotti S., Chen W. et al. // Proc. Natl. Acad. Sci. U. S. A. – 1995. – Vol. 92. – P. 12520–12524. https://doi.org/10.1073/pnas.92.26.12520
Morin R.D. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma / Morin R.D., Mendez-Lago M., Mungall A.J. et al. // Nature. – 2011. – Vol. 476. – P. 298–303. https://doi.org/10.1038/nature10351
Muramatsu M. Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme / Muramatsu M., Kinoshita K., Fagarasan S. et al // Cell. – 2000. – Vol. 102. – P. 553–563. https://doi.org/10.1016/S0092-8674(00)00078-7
Nardini E. Detection of aberrant isotype switch recombination in low-grade and high-grade gastric MALT lymphomas / Nardini E., Aiello A., Giardini R. et al. // Blood. – 2000. – Vol. 95. – P. 1032–1038. PDF
Ngo V.N. A loss-of-function RNA interference screen for molecular targets in cancer / Ngo V.N., Davis R.E., Lamy L. et al. // Nature. – 2006. – Vol. 441. – P. 106–110. https://doi.org/10.1038/nature04687
Nogai H. Pathogenesis of Non-Hodgkin’s Lymphoma / Nogai H., Dorken B., Lenz G. // J. Clin. Oncol. – 2011. – Vol. 29. – P. 1803–1811. https://doi.org/10.1200/JCO.2010.33.3252
Obermann E.C. BCL2 gene aberration as an IPI-independent marker for poor outcome in non-germinal-centre diffuse large B cell lymphoma / Obermann E.C., Csato M., Dirnhofer S. et al. // J. Clin. Pathol. – 2009. – Vol. 62. – P. 903–907. https://doi.org/10.1136/jcp.2009.066597
Ott M.M. The Hans classificator does not predict outcome in diffuse large B cell lymphoma in a large multicenter retrospective analysis of R-CHOP treated patients / Ott M.M., Horn H., Kaufmann M. et al. // Leuk Res. – 2012. – Vol. 36. – P. 544–545. https://doi.org/10.1016/j.leukres.2012.01.022
Ott G. Immunoblastic morphology but not the immunohistochemical GCB / nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL / Ott G., Ziepert M., Klapper W. et al. // Blood. – 2010. – Vol. 116. – P. 4916–4925. https://doi.org/10.1182/blood-2010-03-276766
Pasqualucci L. Inactivating mutations of acetyltransferase genes in B-cell lymphoma / Pasqualucci L., Dominguez-Sola D., Chiarenza A. et al. // Nature. – 2011. – Vol. 471. – P. 189–195. https://dx.doi.org/10.1038%2Fnature09730
Pasqualucci L. Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas / Pasqualucci L., Neumeister P., Goossens T. et al. // Nature. – 2001. – Vol. 412. – P. 341–346. https://doi.org/10.1038/35085588
Pasqualucci L. Analysis of the coding genome of diffuse large B-cell lymphoma / Pasqualucci L., Trifonov V., Fabbri G. et al. // Nat Genet. – 2011. – Vol. 43. – P. 830–837. https://doi.org/10.1038/ng.892
Pui C.H. Central nervous system disease in hematologic malignancies: historical perspective and practical applications / C.H. Pui, E. Thiel // Semin. Oncol. – 2009. – Vol. 36. – P. S2–S16. https://doi.org/10.1053/j.seminoncol.2009.05.002
Rajewsky K. Clonal selection and learning in the antibody system // Nature. – 1996. – Vol. 381. – P. 751–758. https://doi.org/10.1038/381751a0
Ramiro A.R. AID is required for cmyc/IgH chromosome translocations in vivo / Ramiro A.R., Jankovic M., Eisenreich T. et al. // Cell. – 2004. – Vol. 118. – P. 431–438. https://doi.org/10.1016/j.cell.2004.08.006
Ryan R.J. EZH2 codon 641 mutations are common in BCL2-rearranged germinal center B cell lymphomas / Ryan R.J., Nitta M., Borger D. et al. // PLoS One. – 2011. – Vol. 6:e28585. https://doi.org/10.1371/journal.pone.0028585
Rosenwald A. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma / Rosenwald A., Wright G., Chan W.C. et al. // N. Engl. J. Med. –2002. – Vol. 346. – P. 1937–1947. https://doi.org/10.1056/NEJMoa012914
Rosenwald A. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma / Rosenwald A., Wright G., Leroy K. et al. // J. Exp. Med. – 2003. – Vol. 198. – P. 851–862. https://doi.org/10.1084/jem.20031074
Salah A.A. Abushanab. Analysis of Tp53 gene polymorphic variants in predicting of toxic complication in non-Hodgkin’s lymphoma treatment / Salah A.A. Abushanab, Vydyborets S., Gorovenko N., Gartovska I., Kyriachenko S., Rossokha Z. // Hematology. Transfusiology. Eastern Europe. – 2016. – Vol. 2, no. 1. – P. 155–165.
Salah A.A. Abushanab. Evaluation of clinic and laboratory parameters and genetic markers in predicting of toxic complications in treatment of patients with non-Hodgkin’s lymphoma / Salah A.A. Abushanab, Vydyborets S., Gorovenko N., Gartovska I., Kyriachenko S., Rossokha Z. // Hematology. Transfusiology. Eastern Europe. – 2016. – Vol. 2, no. 2. – P. 198–206.
Salah A.A. Abushanab. The influence of genetic factors on the development of different clinical manifestations of toxicity in patients with non-Hodgkin’s lymphoma / Salah A.A. Abushanab, Vydyborets S., Gorovenko N., Gartovska I., Kyriachenko S., Rossokha Z. // Hematology. Transfusiology. Eastern Europe. – 2015. –no. 3 (03). – P. 48–61.
Schmitz R. TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma / Schmitz R., Hansmann ML., Bohle V. et al. // J. Exp. Med. – 2009. – Vol. 206. – P. 981–989. https://doi.org/10.1084/jem.20090528
Shahi P.K. Linfoma B difuso de células grandes / Shahi P.K., Manga G.P. // Med. Clin. (Barc). – 2006. – Vol. 127 (1). – P. 17–21. https://doi.org/10.1157/13089865
Song M.K. Prognostic significance of the Bcl-2 negative germinal centre in patients with diffuse large B cell lymphoma treated with R-CHOP / Song M.K., Chung J.S., Shin D.H. et al. // Leuk. Lymphoma. – 2009. – Vol. 50. – P. 54–61. https://doi.org/10.1080/10428190802626616
Swerdlow S.H. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue (IARC WHO Classification of Tumours). // World Health Organization. – 2008. – 4th edition.
Thieblemont C. The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: A bio-CORAL study / Thieblemont C., Briere J., Mounier N. et al. // J. Clin. Oncol. – 2011. – Vol. 29. – P. 4079–4087. https://doi.org/10.1200/JCO.2011.35.4423
Turner J.J. WHO non-Hodgkin’s lymphoma classification by criterionbased report review followed by targeted pathology review: an effective strategy for epidemiology studies / Turner J.J., Hughes A.M., Kricker A. et al. // Cancer Epidemiol. Biomarkers Prev. – 2005. – Vol. 14. – P. 2213–2219. https://doi.org/10.1158/1055-9965.EPI-05-0358
Tzankov A. Prognostic immunophenotypic biomarker studies in diffuse large B cell lymphoma with special emphasis on rational determination of cut-off scores. / Tzankov A., Zlobec I., Went P. et al. // Leuk. Lymphoma. – 2010. – Vol. 51. – P. 199–212. https://doi.org/10.3109/10428190903370338
Visco C. The t(14;18)(q32;q21) characterizes a subset of patients with diffuse large-B cell lymphoma of germinal center origin with poor outcome: Report from the international DLBCL rituximab-CHOP consortium program study / Visco C., Tzankov A., Xu-Monette Z.Y. et al. // Blood. – 2011. – Vol. 118. – Abstract 949. Full text
Wang X. Negative autoregulation of BCL-6 is bypassed by genetic alterations in diffuse large B cell lymphomas / Wang X., Li Z., Naganuma A. et al. // Proc. Natl. Acad. Sci. USA. – 2002. – Vol. 99. – P. 15018–15023. https://doi.org/10.1073/pnas.232581199
World Health Organization. Pathology and genetics of tumours of haematopoietic and lymphoid tissues // Lyon: International Agency for Research on Cancer. 2001.
